| Drug General Information |
| Drug ID |
D02WRE
|
| Former ID |
DIB011915
|
| Drug Name |
ATS-907
|
| Synonyms |
AK-138 series; ATS-907M1; Rho kinase inhibitor (ophthalmic liquid, glaucoma/ocular hypertension), Altheos
|
| Indication |
Glaucoma [ICD9: 365; ICD10:H40-H42]
|
Investigative |
[1]
|
|---|
| Company |
Asahi Kasei Pharma Corp
|
| Target and Pathway |
| Target(s) |
Rho-associated protein kinase 1 |
Target Info |
Inhibitor |
[1]
|
|---|
| Rho associated protein kinase 2 |
Target Info |
Inhibitor |
[2]
|
|
KEGG Pathway
|
cGMP-PKG signaling pathway
|
|
cAMP signaling pathway
|
|
Chemokine signaling pathway
|
|
Sphingolipid signaling pathway
|
|
Vascular smooth muscle contraction
|
|
TGF-beta signaling pathway
|
|
Axon guidance
|
|
Focal adhesion
|
|
Platelet activation
|
|
Leukocyte transendothelial migration
|
|
Regulation of actin cytoskeleton
|
|
Oxytocin signaling pathway
|
|
Pathogenic Escherichia coli infection
|
|
Shigellosis
|
|
Salmonella infection
|
|
Pathways in cancer
|
|
Proteoglycans in cancer
|
|
MicroRNAs in cancerhsa04022:cGMP-PKG signaling pathway
|
|
Wnt signaling pathway
|
|
PANTHER Pathway
|
Cytoskeletal regulation by Rho GTPase
|
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
|
CCKR signaling map STP00016:Cytoskeletal regulation by Rho GTPase
|
|
Pathway Interaction Database
|
Signaling events mediated by PRL
|
|
RhoA signaling pathway
|
|
Noncanonical Wnt signaling pathway
|
|
EPHB forward signaling
|
|
Thromboxane A2 receptor signaling
|
|
PAR4-mediated thrombin signaling events
|
|
amb2 Integrin signaling
|
|
Integrins in angiogenesis
|
|
EPHA forward signaling
|
|
Stabilization and expansion of the E-cadherin adherens junction
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
PAR1-mediated thrombin signaling events
|
|
N-cadherin signaling eventsrhoa_pathway:RhoA signaling pathway
|
|
Plasma membrane estrogen receptor signaling
|
|
Osteopontin-mediated events
|
|
PLK1 signaling events
|
|
Signaling events mediated by focal adhesion kinase
|
|
Reactome
|
Apoptotic cleavage of cellular proteins
|
|
EPHB-mediated forward signaling
|
|
EPHA-mediated growth cone collapse
|
|
G alpha (12/13) signalling events
|
|
Sema4D induced cell migration and growth-cone collapse
|
|
VEGFA-VEGFR2 Pathway
|
|
RHO GTPases Activate ROCKsR-HSA-3928662:EPHB-mediated forward signaling
|
|
RHO GTPases Activate ROCKs
|
|
WikiPathways
|
G13 Signaling Pathway
|
|
Regulation of Actin Cytoskeleton
|
|
EGF/EGFR Signaling Pathway
|
|
TGF beta Signaling Pathway
|
|
Focal Adhesion
|
|
JAK/STAT
|
|
AGE/RAGE pathway
|
|
Pathogenic Escherichia coli infection
|
|
Regulation of Microtubule Cytoskeleton
|
|
Leptin signaling pathway
|
|
Semaphorin interactions
|
|
Integrin-mediated Cell Adhesion
|
|
GPCR downstream signaling
|
|
Apoptotic execution phase
|
|
MicroRNAs in cardiomyocyte hypertrophy
|
|
Androgen receptor signaling pathwayWP524:G13 Signaling Pathway
|
|
Spinal Cord Injury
|
|
Androgen receptor signaling pathway
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1503). |
|---|
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1504). |
|---|
